Portal de Periódicos da CAPES

In vitro activity of new rifamycins aganst rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

1987; Churchill Livingstone; Volume: 68; Issue: 3 Linguagem: Francês

10.1016/0041-3879(87)90053-5

1878-6006

Jean M. Dickinson, D A Mitchison,

Pneumocystis jirovecii pneumonia detection and treatment

Comparisons were made of the in vitro activity of rifampicin, and the rifamycin derivatives, rifapentine, rifabutin, CGP 29861, CGP 7040 and CGP 27557, against rifampicin-sensitive and rifampicin-resistant strains of Mycobacterium tuberculosis and against the Mycobacterium avium/intracellulare/scrofulaceum (MAIS) complex. The new rifamycins had MICs four to eight times lower than those of rifampicin against sensitive M. tuberculosis strains. Of the 35 rifampicin-resistant strains of M. tuberculosis 31% were sensitive to rifabutin but only 3–11% to the other rifamycins. The proportions of the MAIS strains found to be sensitive were 35% for rifapentine and rifabutin and 85–92% for CGP 29861 and CGP 7040. L'auteur a comparé l'activité in vitro de la rifampicine et des dérivés de la rifamycine-rifapentine, rifabutine, CGP 29 861, CGP 7040 et CGP 27 55-vis-à-vis des souches de Mycobacterium tuberculosis sensibles à la rifampicine et résistantes à la rifampicine et vis-à-vis du complexe Mycobacterium avium/intracellulare/scrofulaceum (MAIS). Les nouvelles rifamycines avient des CIM 4 à 8 fois plus basses que celle de la rifampicine vis-à-vis des souches sensibles de M. tuberculosis. Parmi 35 souches de M. tuberculosis resistantes a la rifampicine, 31% étaient sensibles à la rifabutine, mais seulement 3 à 11% aux autres rifamycines. Les proportions des souches du complexe MAIS trouvées sensibles ont été de 35 en ce qui concernait larifampicine, 50–69% pour CPG 27 557, rifapentine et rifabutine et 85–92 % pour CGP 29 861 et CGP 7040. Se comparó la actividad in vitro de la rifampicina y de derivados de la rifamicina — rifapentina, rifabutina, CGP 29861, CGP 7040 y CGP 27557- contra cepas de Mycobacterium tuberculosis resistentes a la rifampicina y sensibles a la rifampicina y contra el complejo Mycobacterium aviuml/intracellulare/scrofuleceum (MAIS). Las nueuvas rifamicinas tertian MICs 4 a 8 veces más bajas que la de la rifampicina contra cepas sensibles de M. tuberculosis. De un total de 35 cepas resistentes a la rifampicina de M. tuberculosis el 31% eran sensibles a la rifabutina, pero sólo 3–11% a las otras rifamicinas. Las proporciones de cepas de MAIS que resultaron sensibles fueron: 35% para la rifampicina, 50–60% para CGP 27557, rifapentina y rifabutina y 85–92% para CGP 29861 y CGP 7040.